A groundbreaking advancement in the field of transplantation medicine has emerged, promising to address one of the most formidable hurdles: immune rejection. Researchers at Pohang University of Science and Technology (POSTECH), collaborating with Ewha Womans University, have pioneered a novel immunosuppressive delivery system aptly named “Immune-Shield.” This innovative approach circumvents the systemic side effects traditionally associated with immunosuppressants by locally administering the therapeutic agents directly onto organ surfaces. This breakthrough offers a hopeful avenue in improving the prospects of organ and xenotransplantation success.
Organ transplantation remains the definitive treatment for replacing organs irreparably damaged due to trauma or disease. Despite its lifesaving potential, the field is plagued by a severe shortage of viable donor organs worldwide. To combat this deficit, xenotransplantation—the transplantation of organs from other species, particularly animals—has garnered considerable interest. However, the host’s immune system invariably perceives the xenograft as a foreign invader and mounts a robust rejection response, undermining transplantation viability.
Immunosuppressive drugs have been the linchpin in preventing graft rejection. Conventionally, these agents are administered orally or via injections, distributing the drug systemically throughout the body. This indiscriminate distribution, however, presents a paradox. While the medications protect the transplanted organ, they also dampen the body’s overall immune defenses, leaving patients vulnerable to infections and drug-induced toxicities, such as nephrotoxicity. This delicate balance frequently results in adverse outcomes and complicates post-transplant care.
The research team, headed by Professor Hyung Joon Cha from POSTECH’s Department of Chemical Engineering and School of Convergence Science and Technology, alongside collaborators from Ewha Womans University, sought to revolutionize this paradigm. They drew inspiration from the remarkable adhesive properties of mussel-derived proteins, known for their ability to firmly attach to surfaces even in aqueous and highly dynamic environments. Employing this biological principle, the team engineered a sprayable adhesive microgel system capable of delivering immunosuppressants directly onto the organ surface.
This bio-inspired delivery platform, coined “Immune-Shield,” harnesses mussel adhesive proteins to anchor microscopic gel particles embedded with immunosuppressive agents firmly onto the complex and often moist surfaces of biological tissues. The microgels form a uniform, invisible coating that adheres robustly in wet environments, ensuring a stable and sustained local release of therapeutic compounds. This localized application dramatically enhances drug concentration at the graft site while minimizing systemic exposure.
Administered via a facile spray technique, Immune-Shield’s practical deployment is both effective and minimally invasive. The spray application allows for uniform coverage over intricate organ geometries, overcoming challenges associated with traditional drug delivery methods that struggle with organ surface topography and fluid presence. Once applied, the microgel coating functions as a controlled-release reservoir, steadily dispensing the immunosuppressive agents, thereby prolonging therapeutic efficacy without compromising the host’s global immune competence.
Preclinical xenotransplantation experiments validated the Immune-Shield’s potent immunomodulatory effects. Compared to conventional systemic immunosuppressant administration, the localized spray coating significantly attenuated immune cell infiltration and dampened inflammatory cascades within the graft tissues. Impressively, this approach more than doubled the survival duration of transplanted tissues, marking a significant leap forward in graft protection and raising prospects for broader clinical translatability.
Mechanistically, the Immune-Shield forms a physical and chemical barrier that interacts intimately with the organ’s extracellular matrix, modulating local immune interactions at the graft interface. This biophysical shield not only stabilizes the tissue architecture but also mitigates the activation of immune effector cells, including T lymphocytes and macrophages, which are central to acute and chronic rejection processes. The local immunosuppression thus mitigates collateral damage to other organ systems.
Professor Cha highlighted the ingenuity of utilizing mussel adhesive proteins, a molecular innovation originally developed in Korea, to craft this state-of-the-art microgel coating. He emphasized the potential for Immune-Shield to revolutionize transplantation medicine by enhancing immune tolerance and graft survival, especially in the complex arena of xenotransplantation where immune hurdles are exceptionally formidable. He projected that this sprayable system could dramatically improve clinical outcomes and pave the way for wider adoption in transplant protocols.
The implications of Immune-Shield extend beyond organ transplantation. The localized, sustained-release microgel coating platform may be adapted for various biomedical applications requiring precise drug delivery to tissues, including wound healing, tissue engineering scaffolds, and localized cancer therapy. The versatility of mussel-inspired adhesion chemistry offers a new toolkit for targeted therapeutic interventions in challenging biological milieus.
This pioneering research underscores the power of bioinspired engineering in solving complex biomedical challenges. Funded by the Creative Innovation Program of POSCO Holdings and the National Research Foundation of Korea’s Mid-career Researcher Program, the multidisciplinary collaboration between POSTECH and Ewha Womans University represents a beacon of translational science. As research progresses, further clinical trials and regulatory evaluations will determine the scope of Immune-Shield’s integration into medical practice.
In conclusion, Immune-Shield exemplifies a paradigm shift in immunosuppressive therapy by delivering localized, adhesive, and controlled drug release directly to vulnerable transplanted organs. This approach holds the promise of drastically minimizing systemic toxicity, enhancing patient quality of life, and ultimately addressing the persistent challenge of graft rejection. The melding of materials science, chemical engineering, and immunology embodied in this technology heralds a new frontier in transplantation and therapeutic delivery systems worldwide.
Subject of Research: Immunosuppressive drug delivery using mussel-derived adhesive microgels for improved xenotransplantation outcomes.
Article Title: Sprayable proteinic adhesive microgel-based immunosuppressive therapeutic coating for effective xenograft transplantation
News Publication Date: 10-Jan-2026
Image Credits: POSTECH
Keywords: immunosuppression, transplantation, xenotransplantation, mussel adhesive protein, microgel, drug delivery system, biomaterials, organ transplantation, immune rejection, localized therapy, controlled release, bioinspired engineering
Tags: Immune-Shield spray technologyimmunosuppressive drug alternativesimproving graft survival rateslocalized immunosuppressant deliverynovel transplant immunotherapy methodsorgan transplantation immune rejectionPohang University transplant researchpost-transplant immunosuppression advancementsreducing systemic immunosuppressant side effectstargeted drug delivery in transplantationtransplant organ surface treatmentxenotransplantation immune challenges
